Regulation of ferritin:: a specific role for interferon-alpha (IFN-α)?: The acute phase response in patients treated with IFN-α-2b

被引:27
|
作者
Stam, TC
Swaak, AJG
Kruit, WHJ
Eggermont, AMM
机构
[1] Univ Rotterdam Hosp, Daniel den Hoed Canc Ctr, Dept Surg Oncol, Rotterdam, Netherlands
[2] Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Autoimmune Dis, Amsterdam, Netherlands
[3] Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands
[4] Zuiderziekenhuis, Dept Rheumatol, Rotterdam, Netherlands
[5] Univ Rotterdam Hosp, Daniel den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
关键词
acute phase response; adult onset Still's disease; hyperferritinaemia; IFN-alpha;
D O I
10.1046/j.1365-2362.2002.0320s1079.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Adult onset of Still's disease is characterized by very high serum ferritin levels, in disproportion with other acute phase proteins (APPs). Because interferon-alpha (IFN-alpha) was observed to cause hyperferritinaemia in three healthy people without increase of other APPs, we hypothesized that IFN-alpha stimulates specifically the synthesis of ferritin. To test this hypothesis, we studied ferritin and other APP levels in patients treated with IFN-alpha. Patients and methods Fifteen patients treated with IFN-alpha-2b 3-5 times a week, as adjuvant treatment after excision of a high-risk melanoma, were compared with six patients without adjuvant treatment (controls). Serum levels of C-reactive protein (CRP) and secretory phospholipase A(2) (sPLA(2)) were measured using ELISA. Levels of ferritin, alpha 1-acid glycoprotein (AAG) and albumin were determined by nephelometry. Results CRP was decreased significantly after 4 weeks (P < 0.01) in the patients treated with IFN-α compared with the nontreated patients, after 6 months of treatment it was still decreased although not significantly. Ferritin increased significantly in the IFN-α-treated patients: 187% of pretreatment value after 4 weeks and 217% after 6 months (P < 0.01), while ferritin levels decreased in the nontreated patients. AAG increased significantly in IFN-alpha-treated patients (107, 114%) compared with the control-patients (91, 76%) but differences were less compared with CRP and ferritin. sPLA, had a variable course, while albumin remained constant within the normal range in both patient groups. Conclusions IFN-alpha induced a significant increase in ferritin, with a significant decrease in CRP, little increase in AAG, varying response of sPLA2 and no change in albumin. This finding suggests a specific role for IFN-alpha in the synthesis or secretion of ferritin. This mechanism may also be involved in the marked hyperferritinaemia in adult onset of Still's disease.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 50 条
  • [21] Influence of interferon-α2b (IFN-α2b) on the prevention of locally advanced bladder carcinoma in mice
    Otto T.
    Bex A.
    Lümmen G.
    Rübben H.
    Urological Research, 1999, 27 (6): : 489 - 492
  • [22] Monoclonal antibodies as probes to study the interferon-α2b (IFN-α2b) binding domain to receptors
    Blank, VC
    Sterin-Prync, A
    Vidal, A
    Criscuolo, M
    Rategui, LA
    Roguin, LP
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 522 - 522
  • [23] Interferon-alpha (IFN-α) Expression Is Increased in Neonatal Mice During the Innate Response to Respiratory Viral Infection
    Liang, Z.
    Shornick, L.
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2019, 55 : S47 - S48
  • [24] Influence of interferon-α2b (IFN-α2b) on the prevention of locally advanced bladder carcinoma in mice
    Otto, T
    Bex, A
    Lümmen, G
    Rübben, H
    UROLOGICAL RESEARCH, 1999, 27 (06): : 489 - 492
  • [25] Phase I clinical and gene modulatory evaluation of tamoxifen and IFN-α2b
    Thakkar, Snehal G.
    Peereboom, David
    Olencki, Thomas
    Jacobs, Barbara
    Elson, Paul
    Rybicki, Lisa
    Lindner, Daniel J.
    Borden, Ernest C.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2006, 26 (11): : 800 - 803
  • [26] Differential resistance of melanoma cells to treatment with recombinant IFN-α2b and leukocyte IFN
    Ruuth, Kristina
    Berglund, Asa
    Munoz, Varinia
    Lundgren, Erik
    ANTICANCER RESEARCH, 2007, 27 (4B) : 2109 - 2114
  • [27] Novel alpha interferon (IFN-α) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-α2b therapy in a subgenomic replicon system
    Escuret, Vanessa
    Martin, Amaury
    Durantel, David
    Parent, Romain
    Hantz, Olivier
    Trepo, Christian
    Menguy, Thierry
    Bottius, Emmanuel
    Dardy, Jerome
    Maral, Jean
    Escary, Jean Louis
    Zoulim, Fabien
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (12) : 3984 - 3991
  • [28] Outcome of interferon-alpha (IFN-α) treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C
    Tokumoto, T
    Tanabe, K
    Oshima, T
    Ishikawa, N
    Shinmura, H
    Yagisawa, T
    Hashimoto, E
    Fuchinoue, S
    Hayashi, N
    Toma, H
    TRANSPLANTATION, 1999, 67 (07) : S99 - S99
  • [29] Liposomal lactoferrin induced significant increase of the interferon-alpha (IFN-α) producibility in healthy volunteers
    Ishikado, A
    Imanaka, H
    Kotani, M
    Fujita, A
    Mitsuishi, Y
    Kanemitsu, T
    Tamura, Y
    Makino, T
    BIOFACTORS, 2004, 21 (1-4) : 69 - 72
  • [30] An update on pegylated IFN-α2b for the adjuvant treatment of melanoma
    Agarwala, Sanjiv S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1449 - 1459